Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KT 413

Next Previous
X
Search
Drug Profile

KT 413

Alternative Names: IRAKIMiD degraders - Kymera Therapeutics; KT-413; KTX-120

Latest Information Update: 08 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kymera Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action IKZF1 protein degraders; IKZF3 protein degraders; Interleukin-1 receptor-associated kinase degraders
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 21 Nov 2023 Kymera Therapeutics suspends a phase I trial in Follicular lymphoma (Second-line therapy or greater) in USA, and the UK (IV) due to sponsor decision (NCT05233033)
  • 02 Nov 2023 Discontinued - Phase-I for Diffuse large B cell lymphoma (Second-line therapy or greater) in USA (IV)
  • 02 Nov 2023 Discontinued - Phase-I for Follicular lymphoma (Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top